ABT NYSE
Abbott Laboratories
1W: +0.8%
1M: +3.5%
3M: -2.2%
YTD: -15.1%
1Y: -17.0%
3Y: +14.2%
5Y: -3.2%
$103.30
-1.58 (-1.51%)
Weekly Expected Move ±3.5%
$96
$100
$104
$107
$111
Credit Risk of going bust: lower than 80% of companies Debt: 15.2% of company value Bonds: $1.35B held by 411 funds, 57 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.24 (down 99%), Abbott Laboratories would be worth roughly what it owes.
Total debt $32.61B against a stock market value of $181.48B.
Distance to default 9.66 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.81B (short-term plus half of long-term), stock volatility 27.4%; Altman Z 3.28. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.24 (down 99%), Abbott Laboratories would be worth roughly what it owes.
Total debt $32.61B against a stock market value of $181.48B.
Distance to default 9.66 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.81B (short-term plus half of long-term), stock volatility 27.4%; Altman Z 3.28. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships5
As Filer
counterparties named
8
As Counterparty
mentioned by others
2
Rel. Types
2023-01-25
Earliest Filing
2026-03-23
Latest Filing
target: 4
acquirer: 1
Counterparties (Filed by ABT)
5 relationshipsCompanies named in ABT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Exact Sciences Corporation | EXAS | target | Target of the proposed acquisition by Abbott Laboratories | 2026-03-09 | View |
| Badger Merger Sub I, Inc. | — | target | Merger subsidiary involved in the Exact Sciences acquisition | 2026-03-09 | View |
| Exact Sciences Corporation | EXAS | target | Target of the acquisition funded by the notes offering | 2026-02-26 | View |
| Exact Sciences Corporation | EXAS | target | Target company in the merger agreement with Abbott Laboratories. | 2025-11-20 | View |
| Badger Merger Sub I, Inc. | — | acquirer | Wholly owned subsidiary of Abbott Laboratories used as the merger vehicle. | 2025-11-20 | View |
Mentioned As Counterparty
8 mentionsOther companies that named ABT in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| EXAS EXACT SCIENCES CORP | target | Acquired Exact Sciences Corporation in a merger transaction completed on March 23, 2026. | 2026-03-23 | View |
| NVEC NVE CORP /NEW/ | supplier | Supplier Partnering Agreement extended and pricing increased for 2026-2027. | 2025-12-17 | View |
| RJET REPUBLIC AIRWAYS HOLDINGS INC. | partner | Former employer of officer Matthew J. Koscal. | 2025-12-01 | View |
| EXAS EXACT SCIENCES CORP | target | Acquired Exact Sciences Corporation in a merger transaction. | 2025-11-20 | View |
| SENS Senseonics Holdings, Inc. | investor | Purchased up to $25 million of common stock in a private placement conditioned on a public offering. | 2025-05-15 | View |
| NVEC NVE CORP /NEW/ | supplier | Supplier Partnering Agreement amended to extend term and increase pricing for 2025. | 2025-02-13 | View |
| NVEC NVE CORP /NEW/ | supplier | Supplier Partnering Agreement extended and pricing increased for 2024. | 2024-01-03 | View |
| NVEC NVE CORP /NEW/ | supplier | Supplier Partnering Agreement partner and customer of NVE Corporation. | 2023-01-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-21 | Earnings Release; Exhibits | View | |
| 2026-10-21 | Other Events; Exhibits | View | |
| 2026-08-20 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-16 | Earnings Release; Exhibits | View | |
| 2026-04-27 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-04-17 | Other Events; Exhibits | View | |
| 2026-04-16 | Earnings Release; Exhibits | View | |
| 2026-03-23 | Other Events; Exhibits | View | |
| 2026-03-09 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2026-02-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-20 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2026-01-22 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-12 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-11-21 | Temporary Suspension of Trading Under Employee Benefit Plan; Financial Statements and Exhibits | View | |
| 2025-11-20 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2025-10-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-01 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-04-28 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-04-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR